Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 7, 2024; 30(13): 1780-1790
Published online Apr 7, 2024. doi: 10.3748/wjg.v30.i13.1780
Recent clinical trials and optical control as a potential strategy to develop microtubule-targeting drugs in colorectal cancer management
Katsuhiro Kita, Allen Burdowski
Katsuhiro Kita, Allen Burdowski, Department of Biology, St. Francis College, Brooklyn, NY 11201, United States
Author contributions: Kita K and Burdowski A conceived the idea and wrote the manuscript.
Conflict-of-interest statement: The author declares no conflict of interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Katsuhiro Kita, PhD, Assistant Professor, Department of Biology, St. Francis College, 179 Livingston Street, Brooklyn, NY 11201, United States. kkita@sfc.edu
Received: December 27, 2023
Peer-review started: December 27, 2023
First decision: January 10, 2024
Revised: February 8, 2024
Accepted: March 19, 2024
Article in press: March 19, 2024
Published online: April 7, 2024
Processing time: 97 Days and 10.6 Hours
Core Tip

Core Tip: This review article proposes a potentially new approach to utilize photo-switchable microtubule (MT)-targeting drugs in colorectal cancer (CRC). First, we will start the introduction of CRC and current therapy as well as some updates in 2023. Then, we list a popular MT-targeting drug family, taxanes in CRC. As many readers may be aware, taxanes are not really effective in CRC for some reason. Here, we would like to shed light on optically controllable MT-targeting drugs as potential new drug candidates in CRC management.